Fmr LLC Invests $117.98 Million in Upstream Bio, Inc. (NASDAQ:UPB)

Fmr LLC bought a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, Holdings Channel.com reports. The fund bought 7,176,187 shares of the company’s stock, valued at approximately $117,977,000. Fmr LLC owned 0.13% of Upstream Bio as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Moody Aldrich Partners LLC bought a new stake in Upstream Bio during the 4th quarter valued at $1,229,000. Bank of New York Mellon Corp bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $607,000. Rhumbline Advisers bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $275,000. US Bancorp DE purchased a new stake in Upstream Bio in the fourth quarter worth about $27,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Upstream Bio during the 4th quarter worth about $2,225,000.

Upstream Bio Price Performance

NASDAQ:UPB opened at $7.58 on Tuesday. The firm has a 50-day simple moving average of $7.65. Upstream Bio, Inc. has a one year low of $5.14 and a one year high of $29.46.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.